Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

ASRT - Assertio Holdings, Inc. Latest News | Finranks

Home

ASRT

A

Assertio Holdings, Inc. (ASRT)

NCM – Real Time Price. Currency in USD

19.39

-0.14 (-0.72%)

At close: Mar 27, 2026, 4:00 PM EDT

19.37

-0.02 (-0.10%)

After-hours: Mar 27, 2026, 4:14 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?

Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?

Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know

Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 182.8% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates

Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates

Assertio (ASRT) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $3.05. This compares to a loss of $1.65 per share a year ago.

Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the fourth quarter and full year ended December 31, 2025. Mark Reisenauer, Chief Executive Officer, stated: “Our core asset, Rolvedon, continues to represent a meaningful revenue opportunity, as reflected in both our 20.

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.

Videos

No Data

There is no data to display

Press releases

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results

LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the fourth quarter and full year ended December 31, 2025. Mark Reisenauer, Chief Executive Officer, stated: “Our core asset, Rolvedon, continues to represent a meaningful revenue opportunity, as reflected in both our 20.

Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements

Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements. As of January 12, 2026, Nasdaq has determined that Assertio has regained compliance with the Minimum Bid Price Rule, which requires the Company's common stock maintains a minimum bid price of $1.00 per share for a min.

Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an e.

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the “Certificate of Amendment”) on December 19 to implement a one-for-fifteen reverse split of its issued and outstanding common stock (the “Reverse Split”). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on December 26, 2025, and the Company's common stock will begin trading.